Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Pentacel Revised Action Date Is Nov. 2

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.

You may also be interested in...



Sanofi Pasteur’s Five-In-One Vaccine Approved

Next step for Pentacel is the June 25 ACIP Vaccines for Children vote.

Sanofi Pasteur’s Five-In-One Vaccine Approved

Next step for Pentacel is the June 25 ACIP Vaccines for Children vote.

Advisory Committee Recommends Sanofi’s Pentacel Combo Vaccine

Concerns regarding insufficient Haemophilus influenzae type b efficacy data are not great enough for committee members to withhold recommendation.

Topics

UsernamePublicRestriction

Register

PS066176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel